Hermes Arzneimittel GmbH Revenue and Competitors

Berlin, DEU

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Hermes Arzneimittel GmbH's estimated annual revenue is currently $26.3M per year.(i)
  • Hermes Arzneimittel GmbH's estimated revenue per employee is $201,000

Employee Data

  • Hermes Arzneimittel GmbH has 131 Employees.(i)
  • Hermes Arzneimittel GmbH grew their employee count by 49% last year.

Hermes Arzneimittel GmbH's People

NameTitleEmail/Phone
1
Key Account ManagerinReveal Email/Phone
2
Manager CRM & CampaignReveal Email/Phone
3
Brand ManagerReveal Email/Phone
4
Senior ProduktmanagerReveal Email/Phone
5
Junior Brand ManagerinReveal Email/Phone
6
Key-Account-ManagerinReveal Email/Phone
7
Business Development & E-Commerce ManagerReveal Email/Phone
8
Senior Key-Account-ManagerReveal Email/Phone
9
Data integration/ESB managerReveal Email/Phone
10
Digital Marketing ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.3M13149%N/AN/A
#2
$108.1M5389%N/AN/A
#3
$39.2M19525%N/AN/A
#4
$42.4M211-5%N/AN/A
#5
$126.1M44817%$446.2MN/A
#6
$69.3M34528%N/AN/A
#7
$60.1M29953%N/AN/A
#8
$26.5M132-1%N/AN/A
#9
$20.1M10022%N/AN/A
#10
$32.4M16126%N/AN/A
Add Company

What Is Hermes Arzneimittel GmbH?

xxx

keywords:N/A

N/A

Total Funding

131

Number of Employees

$26.3M

Revenue (est)

49%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Hermes Arzneimittel GmbH News

2022-04-06 - BETAISODONA ADVANCED Wund- und Heilgel für eine ...

... Wund- und Heilgel für eine schnellere und bessere Wundheilung. «Zurück zur Übersicht. HERMES ARZNEIMITTEL GMBH 06.04.2022. 2021 Hermes Arzneimittel GmbH.

2022-04-06 - BETAISODONA ADVANCED Wund- und Heilgel für eine ...

... Wund- und Heilgel für eine schnellere und bessere Wundheilung. «Zurück zur Übersicht. HERMES ARZNEIMITTEL GMBH 06.04.2022. 2021 Hermes Arzneimittel GmbH.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$32.8M13124%N/A
#2
$32.8M131N/AN/A
#3
$3.5M131-11%N/A
#4
$26.9M13124%N/A
#5
$16.1M13179%N/A